PCSK9 and atherosclerosis: An orally available antisense oligonucleotide for PCSK9 has recently demonstrated promise in preclinical studies [52], and RNA silencing is currently under investigation to target a range of proteins implicated in the pathophysiology of atherosclerosis (Table 2).